|Home | About | Journals | Submit | Contact Us | Français|
The May guideline summary by Gralla and Raftopoulos, entitled “Progress in the Control of Chemotherapy-Induced Emesis: New Agents and New Studies” (J Oncol Pract 5:130-133, 2009), contained errors.
The following disclosure information was inadvertently omitted:
Although all authors completed the disclosure declaration, the following author(s) indicated a financial or other interest that is relevant to the subject matter under consideration in this article. Certain relationships marked with a “U” are those for which no compensation was received; those relationships marked with a “C” were compensated. For a detailed description of the disclosure categories, or for more information about ASCO's conflict of interest policy, please refer to the Author Disclosure Declaration and the Disclosures of Potential Conflicts of Interest section in Information for Contributors.
Employment or Leadership Position: None Consultant or Advisory Role: Richard J. Gralla, Merck (C), GlaxoSmithKline (C), Helsinn (C), Eisai (C) Stock Ownership: None Honoraria: Richard J. Gralla, Merck, Helsinn; Haralamabas Raftapoulos, Merck Research Funding: Richard J. Gralla, Helsinn Expert Testimony: None Other Remuneration: None